These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Luspatercept: A Review in Transfusion-Dependent Anaemia due to Myelodysplastic Syndromes or β-Thalassaemia. Kang C, Syed YY. Drugs; 2021 Jun; 81(8):945-952. PubMed ID: 33970460 [Abstract] [Full Text] [Related]
10. Luspatercept for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes (PACE-MDS): a multicentre, open-label phase 2 dose-finding study with long-term extension study. Platzbecker U, Germing U, Götze KS, Kiewe P, Mayer K, Chromik J, Radsak M, Wolff T, Zhang X, Laadem A, Sherman ML, Attie KM, Giagounidis A. Lancet Oncol; 2017 Oct 09; 18(10):1338-1347. PubMed ID: 28870615 [Abstract] [Full Text] [Related]
12. Luspatercept as a therapy for myelodysplastic syndromes with ring sideroblasts. Schulz F, Nachtkamp K, Kasprzak A, Gattermann N, Haas R, Germing U. Expert Rev Hematol; 2021 Jun 09; 14(6):509-516. PubMed ID: 34161752 [Abstract] [Full Text] [Related]
20. The prognostic value of serum erythropoietin in patients with lower-risk myelodysplastic syndromes: a review of the literature and expert opinion. Park S, Kelaidi C, Meunier M, Casadevall N, Gerds AT, Platzbecker U. Ann Hematol; 2020 Jan 27; 99(1):7-19. PubMed ID: 31650290 [Abstract] [Full Text] [Related] Page: [Next] [New Search]